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Using bacteria as therapeutic agents against solid tumors is emerging as an area of great potential in the
treatment of cancer. Obligate and facultative anaerobic bacteria have been shown to infiltrate the hypoxic
regions of solid tumors, thereby reducing their growth rate or causing regression. However, a major
challenge for bacterial therapy of cancer with facultative anaerobes is avoiding damage to normal tissues.
Consequently the virulence of bacteria must be adequately attenuated for therapeutic use. By placing an
essential gene under a hypoxia conditioned promoter, Salmonella Typhimurium strain SL7207 was
engineered to survive only in anaerobic conditions (strain YB1) without otherwise affecting its functions. In
breast tumor bearing nude mice, YB1 grew within the tumor, retarding its growth, while being rapidly
eliminated from normal tissues. YB1 provides a safe bacterial vector for anti-tumor therapies without
compromising the other functions or tumor fitness of the bacterium as attenuation methods normally do.
E
ffective tumor targeting and the toxicity of treatments are major problems in current cancer therapy. In
solid tumors, hypoxic regions create a further problem as they are resistant to many treatments1 and are
linked to more malignant phenotypes2. A potential solution is to employ anaerobic bacteria to target the
hypoxic regions to cause tumor regression3,4. Not only have anaerobic bacteria been shown to use chemotaxis to
locate tumors and then cause regression5 but they can also be used as anti-tumor treatment vectors6,7 or as
complements to other therapies8,9.
Intentional use of bacteria in cancer treatment can be dated to the late 19th century with even earlier anecdotal
reports of bacterial efficacy in treating cancer3,10,11. The first reported deliberate attempt at using bacteria
(Streptococcus pyrogenes) to treat an inoperable sarcoma also demonstrated the inherent danger of the technique.
Whilst the tumor and lymph nodes reduced appreciably, the patient died of infection within 9 days of treat-
ment3,10,11.
Consequently, much recent work on bacterial therapies for cancer has focused on non-pathogenic strains or
the need to attenuate bacteria for use in model systems and humans. Bifidobacteria are non-pathogenic obligate
anaerobes and have been successfully used to target tumors and as a therapeutic vectors but do not appear to have
a direct oncolytic effect8,12–14. The spore forming Clostridia are obligate anaerobes with some oncolytic ability and
non-pathogenic and attenuated forms have been used directly and as gene-therapy vectors9,15,16. Tumor coloniza-
tion by Clostridia is strain dependent17,18 and more effective strains such as C. sporogenes have been transformed
to act as improved gene therapy vectors17–19. Clostridial spores will not germinate in aerobic tissues and so are
generally safe for systemic administration17 but may be less effective on small tumors or smaller metastases3,11,15.
Facultative anaerobes, such as Salmonella enterica serovar Typhimurium, can target both small and large
tumors and reduce tumor size8.While wild type strains target tumors, their virulencemay result in the death of the
host20. Attenuation of strains reduces the stress on the host and preferential bacterial colonization of tumors at
ratios of 1,000 to 10,000:1 compared to normal tissues has been reported20,21. Apart from reducing tumor size or
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retarding growth20,22,24, Salmonella strains have also proved effective
against metastasis25–27. When coupled with gene or conventional
therapy, the anti-tumor effects of Salmonella can be enhanced7,20,23.
Several attenuated Salmonella strains have been developed for
tumor targeting studies. SL7207, which has a defect in the aroA gene
and is a derivative of similar attenuated strains28, has been used by
several groups29–33, although it can affect the health of immuno-
compromised mice29,33. Deletions in purI and msbB gave rise to
VNP2000921,34 which has been used for gene-targeted pro-drug ther-
apy35 and tested for oral delivery36 and in clinical trials37,38. StrainA139
and its derivative A1-R24 are leucine-arginine auxotrophs and A1-R
targeted a metastases model26. Defects in guanosine 59-diphosphate-
39-diphosphate synthesis attenuated Salmonella (strain DppGpp)40
which has been shown to be effective as an inducible vector against
CT-26 tumors and metastases23. The different nutritional envir-
onment in a tumor may compensate for the metabolic defects in
these bacteria, thereby allowing effective growth in a tumor but not
in normal tissues20,39.
However, attenuation to reduce virulence in normal tissues might
compromise the function of the bacteria in tumors. A large-scale
study used a transposon library and a custom microarray to identify
a group of Salmonella mutants that had reduced fitness or attenu-
ation in normal tissues41. Their aimwas to identify attenuated strains
that retain their fitness inside tumors. Two classes of attenuated
strains, those with minor or with moderate reductions in tumor
fitness, were identified. STM3120, a severely attenuated SPI-3
mutant, had a minor reduction in tumor fitness and was effective
in PC-3 tumors and somewhat effective in oral administration41. An
aroA mutant, similar to SL7207, had moderately reduced tumor
fitness. However, this study examined bacterial fitness in tumors,
not tumor killing ability.
In this work, we developed a novel synthetic biology approach to
engineering Salmonella to enhance its effectiveness in anti-tumor
therapy. An essential gene (asd) is engineered so that it is under
the control of a hypoxia-conditioned promoter. The normal func-
tions of the bacterium are not compromised by the deletion or muta-
tion of any of its genes. In normal tissues under aerobic conditions,
asd is not expressed, diaminopimelic acid (DAP) is not synthesized
and the bacterium will lyse during growth unless DAP is supplied by
the environment. In tumor bearing nude mice the engineered strain
inhibited tumor growth while not affecting the mice. In contrast, the
original Salmonella strain was lethal to the mice.
Results
Creation of a hypoxia targeted Salmonella strain (YB1). Re-
placement of the essential gene asd from parental Salmonella typhi-
murium strain SL7207 with a construct where this gene is under the
control of hypoxia targeted promoters was achieved by recombineering
technology. In the resulting YB1 strain, the FNR related anaerobic
capable promoter PpepT controls asd transcription while an aerobic
promoter, PsodA, facilitates transcription of antisense asd that blocks
any leakage of asd expression under aerobic conditions (Fig. 1a). If asd is
not transcribed andDAP is not supplied in the environment, lysis of the
YB1 bacteria will occur during bacterial growth.
Several other strain variants were constructed (YB-asd – SL7207
with no asd gene; YB1-pw – as YB1 but with no antisense promoter
for asd; YB1-ew – as YB1 but with the pepT promoter replaced with a
weaker ansB promoter) (Supplementary Fig. S1). Regulation of Asd
expression under high and low oxygen levels was tested. Changes in
Asd protein levels were demonstrated by immunoblotting of myc
tagged Asd. This showed that asd expression in the YB1 (YB1-myc)
strain was controlled by oxygen as expected (Fig. 1b and Sup-
plementary Fig. S2). Strong Asd expression was detected under
anaerobic conditions (YB1-O2) while no expression was observed
under aerobic conditions (YB11O2). In the YB1-pw (YB-myc-pw)
strain without the antisense promoter, leaky Asd expression was
observed under aerobic conditions (PW1O2). No expression of
Asd was observed under either aerobic or anaerobic conditions
(EW1O2 and EW-O2) in strain YB1-ew (YB-myc-ew) with the weak
EW promoter.
All of the strains were tested for growth in LB broth (Fig. 1c-f). Of
the engineered strains in the absence of DAP, only YB1 showed the
combination of growth under anaerobic culture conditions and
repression in the aerobic environment. SL7207 and YB-pw showed
growth in all conditions. YB-asd and YB-ew showed growth only
with the addition of DAP.
Serial reductions in the oxygen level and bacterial concentration
were used to establish the range of conditions under which YB1 and
the other strains could survive in the presence or absence of DAP. On
LB agar plates without DAP, YB1 grew only when oxygen levels
decreased to below 0.5%. Strains YB-asd and YB-ew did not grow
in the absence of DAP, while SL7207 and YB-pw grew in all condi-
tions (Fig. 1g).
Ability of YB1 to invade cancer cells. Breast cancer cell line MDA-
MB-231 samples were incubated with YB1 or SL7207 under oxygen
concentrations below 0.5% or aerobic conditions. After removal of
extra-cellular bacteria and further culturing, confocal microscopy
showed that both SL7207 and YB1 had invaded the breast cancer
cells under anaerobic conditions (Fig. 2a, YB1-O2, SL7207-O2). In
comparison, under aerobic conditions (Fig. 2a, YB11O2, SL72071
O2), YB1 could not survive and only SL7207 was observed in breast
cancer cells (quantification of infection rates is shown in Sup-
plementary Fig S3). In anaerobic conditions, using an annexin
V/PI assay, MDA-MB-231 samples treated with each of the
bacteria showed an increase in the number of dying or apoptotic
cells relative to a blank control (Fig. 2b), with YB1 being somewhat
more effective in causing cell death or apoptosis (P,0.05) (Fig. 2c).
Accumulation of YB1, VNP20009 and SL7207 in tumor and
normal tissues in vivo. Three groups of four-week-old nude mice
were inoculated with breast cancer cells and, when tumor volumes
reached 500–550 mm3, a single dose of SL7207, YB1 or VNP20009
was injected via the tail vein. At varying time points, mice were
euthanized and most organs and tumor were collected, homo-
genized and cultured on LB agar plates with antibiotics and DAP.
CFU/gram was used as a relative measure of the degree of
colonization of the tissues with bacteria.
For SL7207 inoculated mice, 1E103 to 1E107 CFU/gram of bac-
teria were found in all tissues at 6 hours (Fig. 3a). Bacterial levels
increased subsequently with an uncontrolled infection by day 3
(Fig. 3a). The tumor to liver ratio of SL7207 was 2.78:1 at day 3.
Mice started to die on day 7. On day 11, SL7207 levels in liver reached
3.8E109 CFU/gram (Fig. 3a) and after that all mice died.
For YB1 injected mice 6 hours after inoculation, bacterial levels
were approximately the same in all tissues as for the SL7207 inocu-
lated mice (Fig. 3b) though bacteria were eliminated from the blood
of 70% of the mice. After 1 day YB1 was eliminated from the blood
and subsequently the levels in all normal tissues rapidly declined. In
tumor, YB1 levels increased to a plateau of ,1E108 CFU/gram by
day 3 (Fig. 3b). The tumor to liver ratio of YB1 CFU/gram was
,7,000:1 on day 3 and ,20,000:1 on day 7 (Fig. 3b) (P,0.05 on
day 5 and day11; P,0.01 on day 7 and day 26). By day 26, YB1 was
totally eliminated from heart, kidney, lung, lymph node, and spleen.
YB1 was also eliminated from liver in five of the six mice tested,
remaining in one mouse with a CFU/gram of 1.3E103. No YB1
was detected inside bonemarrow within the whole process of experi-
ments.
Like YB1, VNP20009 preferentially accumulated in tumor tissue
(P,0.05) as has been reported21,34. Bacterial levels in tumor reached a
plateau of,3E108 CFU/gram by day 5 (Fig 3c). The best tumor to
liver ratio was,3,900:1 on day 5 (Fig 3c). When compared with the
SL7207 strain, VNP20009 demonstrated quicker clearance from
www.nature.com/scientificreports
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Figure 1 | Construction and testing of tumor-targeting Salmonella strain YB1. (a) Construction of the hypoxia conditioned asd gene expression
cassette. The sense promoter PpepT contains the constitutive promoter P2 and the FNR regulated promoter P1 and PsodA is the antisense promoter.
(b) To test asd expression in response to oxygen, strains YB-myc-EW, YB-myc-PW, and YB1 were cultured under aerobic (1O2) or anaerobic (-O2)
conditions for 24 hours at 37uC. DAP was added to prevent cell lysis under aerobic conditions. Bacterial cell number was quantified by OD600
measurement and total protein was extracted from those bacteria respectively. Asd-myc expression was detected byWestern blotting with loading control
(Supplementary Fig. S2) (c, d) Growth rate of various strains (104 bacteria/ml) under aerobic or anaerobic conditions in LB broth without DAP
(mean6sd, each time point represents three individual experiments). (e, f) as in (c, d) but with DAP. (g) Differentmutant strains at serial dilutions under
decreasing oxygen levels were cultured for 24 hours and bacterial growth was observed. Columns: 1 SL7207; 2 YB-asd; 3 YB1; 4 YB-PW; 5 YB-EW. (Three
independent experiments were performed.)
www.nature.com/scientificreports
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Figure 2 | Salmonella YB1 and SL7207 in breast cancer cells. (a) In vitro cultured breast cancer cells (MBA-MB-231) were exposed to Salmonella YB1
and SL7207 (1: 500,1000) separately under anaerobic (O2,0.5%: YB1 - O2, SL7207 - O2) or aerobic (O2521%: YB1 1 O2, SL7207 1 O2) conditions.
Two hours post-incubation, breast cancer cells were washed and fresh medium containing gentamycin (50 mg/ml) was added to remove extracellular
bacteria. 24,48 hours later, breast cancer cells were collected, stained using an anti-Salmonella antibody (red) and phalloidin to indicate cancer cells
(green) and observed by confocal microscopy.Merged and enlarged images are given. (b,c) Apoptosis and death rate of cancer cells induced by Salmonella
under anaerobic conditions were detected by annexin-V/PI staining and measured by flow cytometry. *, P,0.05.
www.nature.com/scientificreports
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normal organs, but was more slowly eliminated than YB1 from liver
(P,0.05), kidney (P,0.05), spleen (P,0.05), lung, lymph node, and
heart (Fig. 3).
Immuno-staining of sections of tumor and liver confirmed the
distribution of Salmonella bacteria in these tissues. Both YB1 and
SL7207 targeted the tumor, with large amounts of bacteria being
present from day 3 onwards (Fig. 4a). In liver, YB1 decreased and
was almost eradicated by day 7 with little effect on liver struc-
ture (Fig. 4b). For SL7207 treated mice, continuing bacterial
accumulation and liver damage were obvious (Fig. 4b). Enlar-
ged images are shown in Supplementary Fig. S4 (tumor section)
and S5 (liver section).
YB1 targeting of hypoxic and necrotic regions in tumors.
HypoxyprobeTM-1 (pimonidazole hydrochloride) was used as a
hypoxia marker to demonstrate the distribution of Salmonella in
tumors. Immunostaining of breast cancer tumor sections revealed
hypoxic and necrotic areas (Supplementary Fig. S6), which is
consistent with previous reports. After the injection of Salmonella
into tumor-bearing mice, most bacteria accumulated in the
HypoxyprobeTM-1 marked region (Fig. 5a, Supplementary Fig. S6).
Formation of hypoxic regions in a tumor might be due to
disorganization of blood vessel development. The area colonized
by YB1 had little or no blood vessels as indicated by CD31 staining
(Fig. 5b), which suggested colonization by bacteria of the hypoxic
region in the tumor. Staining with a GR-1 antibody to examine the
immune response to bacterial invasion revealed infiltration of Gr-11
host neutrophils into the breast tumor where they appeared to form a
barrier around YB1 (Fig. 5c, 5d).
YB1 inhibited tumor growth in vivo. As YB1 invaded MDA-MB-
231 breast cancer cells in vitro, causing cell apoptosis, its effect in vivo
was measured. Tumor growth (from a volume of,500–550 mm3 at
bacterial inoculation) in YB1 treated mice was initially inhibited and
then delayed relative to PBS treatedmice (P,0.05 on day 3, P,0.001
from day 5 to day 21) (Fig. 6a). Little further tumor growth was seen
in SL7207 treated mice as bacterial toxicity caused death between
days 7 and 11 (Fig. 6a). Mice treated with YB1 (with or without a
tumor) and YB-asd treated tumor free mice survived more than 25
days, as did mice (with or without a tumor) treated with PBS
(Fig. 6b). SL7207 treated mice started to die on days 5 and 7 with
all mice dying by days 8 and 11 (without or with a tumor, re-
spectively). SL7207 treated mice with a tumor had a slightly better
survival rate (Fig. 6b).
While the reduction in tumor growth in YB1 treated mice was
marked compared with PBS treated mice, the tumor was still grow-
ing. Treatment of tumor bearing mice with the therapeutic agent 5-
FU showed only a small reduction (P.0.05) in tumor growth relative
to PBS treatment (Fig 6c) although 5-FU was toxic to breast cancer
cells (Supplementary Fig. S7). However, when 5-FUwas given to YB1
infected tumor bearing mice, much greater, and statistically signifi-
cant, reductions in tumor size were observed thanwith the individual
treatments (Fig 6c).
Comparison of strains YB1 and VNP20009 in tumor targeting
and regression. A single dose of VNP20009 or YB1 was injected
via the tail vein to mice bearing a breast tumor of ,360 mm3 and
tumor size was measured every two days. Both YB1 (P,0.01) and
VNP20009 (P,0.05) could delay tumor growth when compared
with a PBS treatment group. However, YB1 showed greater tumor
inhibition than VNP20009 (P,0.05) (Fig 6d).
The health of these mice was monitored by measuring body
weight. In the first two days after innoculation, both YB1 and
VNP20009 treatment groups showed significant body weight loss
compared with the control group (P,0.01) but not to each other
(Supplementary Fig. S8). The body weight of both groups started
recovering after 3 to 5 days, and no mouse died due to the bacterial
treatment.
Discussion
Anaerobic bacteria provide an important treatment opportunity in
cancer therapy due to their ability to target the hypoxic region of solid
tumors that is resistant to conventional treatment1,3. If Salmonella, a
facultative anaerobic bacterium, is to be a successful treatment agent
in anti-cancer therapy, bacterial virulence in the host needs to be
addressed11. In most cases attenuated forms are created and used as
Figure 3 | CFU test of YB1, SL7207, and VNP20009 in breast tumor
bearing nude mice. Nude mice with an MBA-MB-231 tumor received
temporal vein injections of YB1, SL7207 or VNP20009. Mice were
euthanized at the indicated time points and blood, heart, kidney, liver,
lung, lymph node, spleen and tumor tissues were collected and
homogenized and bacterial accumulation evaluated. In SL7207 (a) YB1 (b)
or VNP20009 (c) treated mice, CFU counts per gram of most normal
organs and tumor (red line) are shown over time (mean6sd, each time
point represents three individual experiments with 2 mice for each
experiment). Statistical significance of tumor group vs. all other groups:
*. * P,0.05; **P,0.01.
www.nature.com/scientificreports
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test therapeutic agents24,29,34,40. However the mutations required to
attenuate a bacterium might also compromise its tumor targeting
and killing ability. This was suggested as a possible reason for the
poor performance of VNP20009 in clinical trials11. Recently, a sys-
tematic study of Salmonella mutants41 partially addressed this issue
by identifying several attenuated mutant bacteria with either mild
or moderate reductions in tumor fitness. Tumor killing by these
mutants could not be examined41.
An alternative approach taken here is to use recombineering to
make Salmonella not viable in normal tissues by placing an essential
gene, asd, under the control of a hypoxia-induced promoter. The asd
gene of Salmonella encodes an enzyme essential for the synthesis of
DAP, which is itself an essential component of the bacterial cell wall
and not present in mammalian systems7. With asd expressed only in
hypoxic conditions the bacterium is able to grow readily under hyp-
oxia, but will lyse under normal growth conditions. Thus Salmonella
can be converted from a facultative to an ‘‘obligate’’ anaerobe, ren-
dering it safe in normal tissues. Previously, programmed bacterial
lysis by conditioning asd expression on a supplied nutrient (arabi-
nose) was demonstrated as a vaccine system7.
Regulation of the fumarate and nitrate reduction gene (fnr) is
involved in the switch between aerobic and anaerobic growth42.
Promoters containing FNR binding sites are activated under hyp-
oxia43. Such a case was demonstrated with the pepT promoter to
create a potential gene therapy vector only expressed in hypoxic
regions43. Here, the pepT promoter (PpepT) was used to drive
expression of asd, conditional on hypoxia, in a recombineered ver-
sion of Salmonella SL7207 (YB-pw) with the aim of limiting bacterial
viability to hypoxic regions. In the engineered strain, the asd gene
was replaced with a PpepT-asd construct. However, this strain was
still able to grow under normal oxygen levels. To prevent leakage
from the pepT promoter, an antisense promoter of the sodA gene,
which is negatively regulated by FNR44, was added to the PpepT-asd
construct to make the strain YB1. This effectively inhibited the
growth of Salmonella, as shown in Fig. 1c-f where YB1 could only
grow in the absence of DAP under anaerobic but not aerobic condi-
tions. Another asd based cell lysis system also required anti-sense
transcription for efficacy7. An alternate construct using the ansB
promoter (YB-EW) proved ineffective under anaerobic conditions,
perhaps due to the construct used being a less efficient promoter.
In the absence of DAP, YB1 was the only strain that had the
combination of growth under anaerobic but not aerobic conditions.
A detailed titration of oxygen level and bacterial concentration
showed that, in the absence of DAP, YB1 was only viable at oxygen
levels below 0.5% (Fig. 1g). Unlike SL7207, YB1 only infiltrated
the MDA-MB-231 breast cancer cells under anaerobic conditions.
However, it was more effective at inducing apoptosis or cell death,
possibly due to the anaerobic expression of asd being stronger under
the hypoxia conditioned promoter as compared to the wild type one.
SL7207, YB1 and an attenuated Salmonella strain VNP20009 were
able to infiltrate MDA-MB-231 tumors induced in nude mice, as
evidenced by the considerable number of bacteria found in the tumor
and the considerable tumor damage observed. Although quiescent
YB1 cells appear to persist briefly in aerobic tissues in the absence of
DAP45, YB1 was effectively cleared from normal tissues. By 3 days
post infection, bacteria were barely detectable in liver. VNP20009
was somewhat less effectively cleared from normal tissues than YB1
and less effective at reducing tumor size. SL7207, despite being an
attenuated vaccine strain, had a similar effect on normal and tumor
cells and killed all mice by 11 days post infection with substantial
bacterial induced liver destruction apparent. While SL7207 might
not affect immuno-competent mice, in the system studied here the
conversion of SL7207 to the ‘‘obligate’’ anaerobic YB1 prevented
bacterial killing of the mice while maintaining, or enhancing, tumor
killing ability. YB1 appeared to be more effective on smaller tumors
(Fig. 3a and d).
Figure 4 | Paraffin section test of YB1 and SL7207 in tumor and liver. The distribution of Salmonella in tumor. (a) and liver (b) of breast tumor bearing
mice over time was demonstrated in tissue paraffin sections by immuno-staining. (Arrows: Salmonella).
www.nature.com/scientificreports
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A more detailed examination of the effect of YB1 in tumors
showed that its design as an ‘‘obligate’’ anaerobe was effective in that
it was tightly confined to the hypoxic regions of tumors and kept
distant from blood vessels. As bacteria are expected to induce a host
immune response, neutrophils were found in the YB1 infected
tumors. YB1 and neutrophils aligned against each other with neu-
trophils possibly acting as a barrier against further bacterial spread.
YB1may enhance tumor killing by strongly attracting neutrophils to
the tumor.
However, YB1 did not totally inhibit breast tumor growth. It is
common for bacterial treatment of tumors to be used in conjunction
with drugs or as a gene therapy agent to deliver a drug or pro-drug to
the tumor environment8,9,18,19. Consequently, the anti-cancer drug 5-
FU was also administered to the tumor bearing mice. When com-
pared with untreated mice, YB1 retarded tumor growth with an
effectiveness greater than that of the drug 5-FU alone. In combina-
tion, YB1 and 5-FU were even more effective. SL7207 was too toxic
and was lethal to the mice before effects on tumor growth could be
observed.
The precise modification of Salmonella strain SL7207, by placing
an essential gene under a hypoxia conditioned promoter, as per-
formed here has successfully converted the bacterium to an ‘‘oblig-
ate’’ anaerobe, thereby removing the lethal toxicity of the host strain
while maintaining its tumor targeting and possibly enhancing its
tumor killing abilities. YB1 has shown comparable or better tumor
colonization, to other bacterial anti-tumor agents such as Chlostri-
dia17,18 and other Salmonella strains5,24,34,43. While the ease of modi-
fyingChlostridia to produce gene therapy vectors17,18 has improved46,
Salmonella can be readily transformed using long-established tech-
niques andYB1 could be developed similarly. YB1-like bacteria could
have the advantages of an obligate anaerobic bacterium while main-
taining the chemotaxic properties5,22 and ability to target meta-
stasis25–27 of Salmonella.
Conditioning Salmonella growth on hypoxia provides an alterna-
tive to conventional attenuation techniques, which require a muta-
tion of the bacteria to compromise some normal function. The
recombineered ‘‘obligate’’ anaerobe YB1 represents a new direction
in producing bacterial therapeutic agents for cancer.
Methods
Bacterial strains, animals, cell lines, enzymes and chemicals. S. typhimurium strain
SL7207 was kindly provided by Dr. B. A. D. Stocker28. S. typhimurium strain
VNP20009 was bought from the American Type Culture Collection (ATCC)
(202165). Four-week-old female Nude-Mice were purchased from the Laboratory
Animal Unit of The University of Hong Kong. The research protocols were approved
by the Committee on the Use of Live Animals in Teaching and Research of the
University of Hong Kong (CULATR 1685-08). The breast cancer cell line MDA-MB-
231 was from the ATTC (HTB-26TM) and was maintained in DMEM supplemented
with 10% FBS, penicillin and streptomycin. Enzymes were fromNewEngland Biolabs
and chemicals were from Sigma. Antibiotic working solutions were prepared as
Figure 5 | Confinement of YB1 in the tumor. (a) YB1 and the hypoxic region are indicated by staining with anti-Salmonella (green) and anti-
hypoxyprobe (red) antibodies, respectively. DNA is indicated byDAPI staining (purple). H: hypoxic area. V: viable area. (b) Blood vessels in the tumor are
shown by an anti-CD31 antibody (red, arrows). (c) Immunocytes were detected with an anti-Gr-1 antibody (red). (d) An overview of YB1 and
immunocyte distribution in tumors.
www.nature.com/scientificreports
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follows: Chloramphenicol, 25 mg/ml in methanol; Ampicillin, 100 mg/ml;
Kanamycin, 50 mg/ml; Gentamycin, 50 mg/ml. Strains were supplied with 50 mg/ml
DAP where noted.
Gene cloning and Plasmid construction. Bacteria and plasmids used or created here
are given in Supplementary Table S1 and primers used are in Supplementary Table S2.
The asd gene and the promoter region of the pepT gene were cloned from the
chromosome of SL7207 by PCR with primer pairs asd-C-F and asd-C-R, pepT-F and
pepT-R (preheating at 95uC for 5 mins, followed by 30 cycles of denaturing at 95uC
for 30 seconds, annealing at 60uC for 30 seconds, elongation at 72uC for 1 min, with
final extension at 72uC for 10 minutes, and then cooling to room temperature) whilst
asd-myc was generated with the asd-C-F and asd-C-myc-R primer pair. PansB and
PsodA (promoters of ansB and sodA) constructs were generated by an annealing
process with oligonucleotide pairs ansB-F and ansB-R, sodA-F and sodA-R (10 mM
forward and reverse primers were mixed and heated at 95uC for 5 mins, and placed at
room temperature for 30 mins). The chloramphenicol resistance gene (cm) was
amplified by PCRwith primers cm-F and cm-R from a ploxp-cm-loxp template47. The
plasmids for the asd expression vectors were built on the backbone of pBluescript II
SK (pBSK) which was digested by HindIII, XhoI, NotI and PstI. After ligation by T4
ligase, plasmids pYB1 (pBSK-cm-PpepT-asd-PsodA), pYB1-myc (pBSK-cm-PpepT-
asd-myc-PsodA), pYB-pw (pBSK-cm-PpepT-asd), pYB-myc-pw (pBSK-cm-PpepT-
asd-myc), pYB-ew (pBSK-cm-PansB-asd-PsodA), and pYB-myc-ew (pBSK-cm-
PansB-asd-myc-PsodA) were generated.
Construction of oxygen sensitive Salmonella mutant (YB1). The l-Red
recombination system (plasmid pSim6; a gift from Dr. Donald Court)48 was used to
replace the asd gene with the cm-PpepT-asd-sodA genetic circuit in SL7207. As a first
step the target asd gene was generated with a ploxp-cm-loxp template in a PCR
reaction, electroporated into recombination-competent cells and selected on
chloramphenicol Luria-Bertani (LB) plates. Antibiotic resistance genes were removed
by site-specific Cre/loxP mediated recombination by transformation of plasmid
p705cre-Km, generating the strain YB-asd. Next, the cm-PpepT-asd-sodA genetic
circuit was amplified from plasmid pYB1 and, after recombineering, the correct
colony was selected and confirmed by PCR giving strain YB1. Strains YB1-his, YB-
pw, and YB-ew were constructed similarly with the plasmids pYB1-myc, pYB-pw,
pYB-pw-myc, pYB-ew, and pYB-ew-myc as templates, respectively.
Growth of Salmonella strains and mutants under aerobic and anaerobic
conditions. Bacterial strains were grown in LB medium at 37uC, with shaking at
220 rpm over night. Aerobic conditions were achieved by shaking in broth, and
anaerobic cultures were either grown in anaerobic tubes or an anaerobic jar
(Mitsubishi Gas Chemical Company). Overnight cultures of Salmonella strains
SL7207, YB-asd, YB1, YB-pw, and YB-ew were counted and diluted into samples at
5E104 colony forming units (CFU)/ml, with each strain divided into two groups
(with or without DAP) in LB broth. OD600 was measured every 30 minutes for
aerobic cultures, and each hour for anaerobic cultures from 0 hours to 24 hours. For
LB agar plate assays, an anaerobic jar was applied to generate different oxygen
concentrations by combinations of AnaeroPacks andmonitored by an oxygen meter.
Ten serial dilutions of individual drops from a high concentration of 5E106 CFU/ml
to 5E101 CFU/ml, where each drop contained 10 ml of bacterial culture, were added
to plates that were cultured in an anaerobic jar at 37uC for 2 days.
Immunoblotting. 24-hour cultures of YB1-myc, YB-myc-pw, and YB-myc-ew under
aerobic or anaerobic conditions in LB with DAP were collected and lysed in RIPA
Figure 6 | Repression of tumor growth by Salmonella strains. (a) Tumor volume (initial size,500–550 mm3) inmice injected with YB1, SL7207 or PBS
(n510, mean6sd). SL7207 treatedmice died by day 11. Statistical significance of YB1 group vs. PBS group*. (b) Survival chart for tumor free and tumor
bearing mice treated with YB1, SL7207, YB-asd or PBS, respectively (n510 each). (c) Tumor bearing mice were treated with YB1 or PBS (n524 each).
After three days, 5-FU was injected i.p. (60 mg/kg) to half the mice of each group (n512) and repeated every three to four days for 2 weeks. Statistical
significance of YB115-FU group vs. PBS group*; YB115-FU group vs. YB1 group#. (d) Tumor volume (starting size,360 mm3) inmice after treatment
with VNP20009, YB1, or PBS, respectively (n56, mean6sd). Statistical significance of YB1 group vs. VNP20009 group*. Significance symbols *, #
P,0.05; **, ## P,0.01; ***, ### P,0.001.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 436 | DOI: 10.1038/srep00436 8
buffer (50 mMTris pH7.4, 150 mMNaCl, 1 mMEDTA, 0.1%SDS, 1%TritonX-100,
1% Na-Deoxycholate). Protein extracts in the amount equivalent to 5E108 CFU of
bacteria were used for each sample. 20 mg of total protein was subjected to SDS-
PAGE, followed by incubation with a c-myc-tag antibody (Invitrogen) overnight at
4uC then with a secondary antibody at room temperature for 1 hour.
Chemiluminescence was detected using an ECL kit (Amersham Life Science)
according to the manufacturer’s instructions.
Salmonella invasion of breast cancer cells in vitro. Salmonella and MDA-MB-231
cells were prepared and co-cultured at a ratio of 1000,500:1 for 2 hours under
anaerobic (O2,0.5%) or aerobic conditions. The cells were thenwashedwith PBS and
cultured in gentamycin supplemented medium to remove extracellular bacteria.
24 hours later, cells were fixed in paraformaldehyde (4%) and stained with an anti-
Salmonella antibody (1:500, Abcam) overnight at 4uC. A Cy3 conjugated secondary
antibody was added and incubated for 1 hour at room temperature. Then FITC
conjugated Phalloidin (1:1000) was applied to indicate cell boundaries. Images were
observed under a confocal microscope. Cancer cell apoptosis and death induced by
bacteria under anaerobic conditions were detected by an annexin V-PI kit (Biovision)
according to manufacturer’s instructions. As shown by flow cytometry, annexin
V1/PI- cells are apoptotic and annexin V1/PI1 cells are dead.
MTT cytotoxicity assay.MDA-MB-231 breast cancer cells were seeded in a 96-well
plate (3,000 cells/well) and allowed to adhere to the plates overnight. Various
concentrations of 5-FU (5-fluorouracil) (1 mg/ml, 10 mg/ml, 20 mg/ml, 50 mg/ml,
100 mg/ml, 200 mg/ml, 500 mg/ml and 1000 mg/ml) were added to the cells and
further cultured for 24, 48, and 72 h. After each time period, media was removed and
100 ml of MTT (methylthiazole tetrazolium, 0.5 mg/ml in DMEM without phenol
red) was added to each well and incubated for 4 h at 37uC. Formazan crystals thus
formed were solubilized in 200 ml of DMSO (dimethyl sulphoxide) by incubating
with shaking for 10 min at room temperature. Absorbance was measured at 570 nm.
The cytotoxicity of 5-FU on breast cancer cell was calculated by ([A]control - [A]test)/
[A]control, where [A]test is the absorbance of the test sample and [A]control is the
absorbance of the control sample containing medium but without 5-FU treatment.
Tumor-bearing nude-mice. 5E105 MDA-MB-231 cells were inoculated at the fat
pad of four-week-old nudemice. The tumor volumes were calculated by the following
formula: 4/33 p3 (h3w2) / 8, h5 height and w5width.When the tumors grew to
about 500–550 mm3 (15–19 days), mice were divided into groups for experiments. If
tumors reached 20 mm in any dimension49 (or,4000 mm3), mice were euthanized.
Tomeasure the effect of bacterial inoculation onmouse survival and tumor growth,
two groups of 10 mice were treated with either YB1 (5E107 CFU) or SL7207
(5E107 CFU), and 6 mice were treated with PBS, with a volume of 100 ml injected
through the tail vein (i.v.). Tumor size (with an initial volume of,500–550 mm3)was
measured by caliper every 2 to 3 days. Mouse survival rate was recorded. For a
comparison of VNP20009 and YB1, an additional two groups of 6 mice with smaller
tumors (,360 mm3) were administrated with same dose (5E107 CFU) of
VNP20009 or YB1.
To measure the bacterial distribution after inoculation, mice treated by the same
method as above were sacrificed at several time points (a total of 6 mice each for the
YB1 and SL7207 treated groups for each time point and 5 mice for the VNP20009
treated group for each time point). Tissues were weighed, homogenized, serially
diluted in PBS and plated with the required antibiotics and DAP. CFU were counted
after two days growth. The experiments involving YB1 and SL7207 treatments were
repeated three times with two mice per time point per experiment and the experi-
ments with VNP20009 were repeated two times with 2–3 mice per time point per
experiment.
A possible synergistic effect of YB1 and 5-FU, was tested in 48 tumor-bearing mice
that were divided into four groups with 12 mice each and treated with PBS, PBS with
5-FU (60 mg/Kg), a single dose of YB1 (5E107 CFU) or a single dose of YB1
(5E107 CFU) plus 5-FU. For the 5-FU-treatmenmt groups, 5-FU was intra-peri-
toneal (i.p) injected every four days starting from day 3 after bacterial injection.
Four groups of 10 healthy nude mice were i.v. injected with 5E107 CFU of YB1,
SL7207, YB-asd or PBS respectively, and observed for survival.
Histology. Bacteria and PBS treated tumor bearing mice were injected with a
hypoxyprobe-1 solution (60 mg/kg) by i.p. 10,40 min before euthanasia. Tissues
were removed from these mice and immediately fixed in 4% paraformaldehyde,
paraffin embedded and sectioned into 5 mMslices. Hypoxic regions and blood vessels
were visualized by mouse anti-hypoxyprobe-1 (hpi) or polyclonal goat anti PECAM1
(CD31) (Santa Cruz) antibodies, respectively. Salmonella and immunocytes were
separately detected by rabbit anti-Salmonella (Abcam) or rat anti-mouse GR-1
(Bioscience) antibodies. Bound primary antibodies were detected using fluorescence
conjugated secondary antibodies or horseradish peroxidase conjugated secondary
antibodies which then developed in DAB solution (Daco). Pictures were taken under
a fluorescence microscope or a light microscope.
Statistical analysis. Statistical analysis was calculated with the Student’s t test, with
P,0.05 considered as significant.
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